Drugmakers including Pfizer (PFE), Bristol-Myers Squibb (BMY) and Sanofi (SNY) plan to raise US list prices on at least 250 branded medications, including COVID-19 treatments, cancer cell therapies and vaccines, at the start of 2025, Reuters reported Tuesday, citing data from the healthcare research firm 3 Axis Advisors.
Most of the price hikes are below 10% and are to list prices, which do not include rebates and discounts, the report said. The median price increase is 4.5%, according to the report.
Some drug list prices will decrease, including Merck's (MRK) diabetes drugs Januvia and Janumet, the report said.
Pfizer, Bristol-Myers Squibb, Sanofi, and Merck did not immediately reply to MT Newswires' requests for comment.
(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.